scispace - formally typeset
Search or ask a question
Institution

Beaumont Health

NonprofitRoyal Oak, Michigan, United States
About: Beaumont Health is a nonprofit organization based out in Royal Oak, Michigan, United States. It is known for research contribution in the topics: Medicine & Population. The organization has 1483 authors who have published 1448 publications receiving 15407 citations. The organization is also known as: William Beaumont Health System & Beaumont Hospitals.


Papers
More filters
Journal ArticleDOI
TL;DR: Episode payments were higher for TAVR, despite shorter length of stay, and center SAVR volume was inversely associated with payments, which will be increasingly important to address value-based reimbursement in valve replacement surgery.

15 citations

Journal ArticleDOI
TL;DR: Despite well-established aortic diameter threshold guidelines, marked variation exists both at the hospital level and in terms of the physician's rationale for the management of elective AAA repairs, demonstrating the challenge of providing uniform care for patients with AAAs despite established guidelines.

15 citations

Journal ArticleDOI
TL;DR: The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination.
Abstract: The use of multiple drug regimens is increasingly recognized as a tacit requirement for the management of hypertension, a necessity fueled in part by rising rates of metabolic syndrome and diabetes. By targeting complementary pathways, combinations of antihypertensive drugs can be applied to provide effective blood pressure control while minimizing side effects and reducing exposure to high doses of individual medications. In addition, combination therapies, including angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs), have the added benefit of reducing cardiovascular mortality and morbidity over other dual therapies while providing equivalent blood pressure control. It is possible that angiotensin receptor blockers (ARBs), which unlike ACE inhibitors are minimally affected by upregulation of alternative pathways for angiotensin II accumulation following long-term treatment, would also provide such outcome benefits. At issue, however, is maintaining patient compliance, as adding medications is known to reduce adherence to treatment regimens. The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination. The areas where long-term data are lacking, notably clinical information regarding minorities and women, will also be discussed.

15 citations

Journal ArticleDOI
TL;DR: In the largest contemporary US cohort reported to date, most patients undergoing diagnostic catheterization before noncardiac surgery are asymptomatic, and although randomized clinical trials have found no benefit in outcomes, revascularization is recommended in nearly half of these patients.
Abstract: Importance Many patients undergo cardiac catheterization and/or percutaneous coronary intervention (PCI) before noncardiac surgery even though these procedures are not routinely indicated. Data on this cohort of patients are limited. Objective To describe the characteristics, angiographic findings, and treatment patterns of clinically stable patients undergoing cardiac catheterization and/or PCI before noncardiac surgery in a large national registry. Design, Setting, and Participants This study is a retrospective, descriptive analysis of National Cardiac Data Registry CathPCI Registry diagnostic catheterization and PCI data from July 1, 2009, through December 31, 2014. Data analysis was performed from April 21, 2015, to January 4, 2016. The study included 194 444 patients from 1046 sites who underwent coronary angiography before noncardiac surgery. Patients with acute coronary syndrome, cardiogenic shock, cardiac arrest, or emergency catheterization were excluded. Main Outcomes and Measures Demographic characteristics, preprocedure noninvasive testing results, angiographic findings, and treatment recommendations are summarized. Among the 27 838 patients who underwent PCI, procedural details, inpatient outcomes, and discharge medications are reported. Results Of the 194 444 included patients, 113 590 (58.4%) were male, the median age was 65 years (interquartile range, 57-73 years), and 162 532 (83.6%) were white. Most were overweight or obese (152 849 [78.6%]), and 78 847 (40.6%) had diabetes mellitus. Most patients were asymptomatic (117 821 [60.6%]), although 112 302 (57.8%) had been taking antianginal medications within 2 weeks of the procedure. Prior noninvasive stress testing was reported in 126 766 (65.2%), and results were positive in 109 458 (86.3%) of those with stress data. Obstructive disease was present in 93 447 (48.1%). After diagnostic angiography, revascularization with PCI or bypass surgery was recommended in 46 380 patients (23.8%) in the overall cohort, 27 191 asymptomatic patients (23.1%), and 45 083 patients with obstructive disease (48.3%). In the 27 191 patients undergoing PCI, 367 treated lesions (1.3%) were in the left main artery and 3831 (13.8%) in the proximal left anterior descending artery. A total of 11 366 patients (40.8%) received drug-eluting stents. Complications occurred in a few patients, with a catheterization-related mortality rate of 0.05%. Conclusions and Relevance In the largest contemporary US cohort reported to date, most patients undergoing diagnostic catheterization before noncardiac surgery are asymptomatic. The discovery of obstructive coronary artery disease is common, and although randomized clinical trials have found no benefit in outcomes, revascularization is recommended in nearly half of these patients. The overall findings highlight management patterns in this population and the need for greater evidence-based guidelines and practices.

15 citations

Journal ArticleDOI
Charles C. Vu1, Kevin Blas1, T. Lanni1, Gary S. Gustafson1, Daniel J. Krauss1 
TL;DR: One-way sensitivity analyses of the results found brachytherapy boost to be cost-effective over a wide range of cost, utility, and cancer progression rate assumptions.

15 citations


Authors

Showing all 1494 results

NameH-indexPapersCitations
Barry P. Rosen10252936258
Praveen Kumar88133935718
George S. Wilson8871633034
Ahmed Ali6172815197
Di Yan6129511437
David P. Wood5924312154
Brian D. Kavanagh5832215865
James A. Goldstein4919312312
Kenneth M. Peters461976513
James M. Robbins451578489
Bin Nan441395321
Inga S. Grills432176343
Sachin Kheterpal431698545
Craig W. Stevens421646598
Thomas Guerrero41935018
Network Information
Related Institutions (5)
Mayo Clinic
169.5K papers, 8.1M citations

91% related

Cleveland Clinic
79.3K papers, 3.4M citations

91% related

Rush University Medical Center
29K papers, 1.3M citations

90% related

Cedars-Sinai Medical Center
26.4K papers, 1.2M citations

89% related

Memorial Sloan Kettering Cancer Center
65.3K papers, 4.4M citations

89% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20232
202220
2021253
2020210
2019166
2018161